The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Zhang, L., Wang, X., Li, Y., Han, J., Gao, X., Li, S., & Wang, F. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.464 · Cited by 27
Qin, J., Sun, X., Ma, Y., Cheng, Y., Ma, Q., Jing, W., Qu, S., & Liu, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116594 · Cited by 29
Strategies for developing PD-1 inhibitors and future directions
Chen, W., Huang, Y., Pan, W., Xu, M., & Chen, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115113 · Cited by 28
Self-citationWang, Y., Jia, Z., Liang, C., He, Y., Cong, M., Wu, Q., Tian, P., He, D., Miao, X., Sun, B., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00507-x · Cited by 29
Wang, S., Park, S. H., Lim, J. S., Park, Y., Du, L., & Lee, J. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01291-4 · Cited by 26
Pedrani, M., Salfi, G., Merler, S., Testi, I., Cani, M., Turco, F., Trevisi, E., Tortola, L., Treglia, G., Tanna, G. L. D., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.04.011 · Cited by 27
Inflammation and tumor immune escape in response to DNA damage
Nihira, N. T., Kudo, R., & Ohta, T. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.005 · Cited by 27
Self-citationBoll, L. M., de Oca, S. V. M., Camarena, M. E., Castelo, R., Joaquim Bellmunt, B., Perera‐Bel, J., & Albà, M. M. (2025) · Nature Communications · doi:10.1038/s41467-025-56462-0 · Cited by 30
Zhang, H., Wang, J., Li, J., Zhou, X., Yin, L., Wang, Y., Gu, Y., Niu, X., Yang, Y., Ji, H., et al. (2021) · Cancer Science · doi:10.1111/cas.14813 · Cited by 28
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway
Luo, Z., Wang, J., Zhu, Y., Sun, X., He, C., Cai, M., Ma, J., Wang, Y., & Han, S. (2021) · Neoplasia · doi:10.1016/j.neo.2021.08.002 · Cited by 27
Self-citationPalicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020236 · Cited by 25
Dong, M., Qian, M., & Ruan, Z. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005270 · Cited by 28
Meliante, P. G., Barbato, C., Zoccali, F., Ralli, M., Greco, A., VINCENTIIS, M. D., Colizza, A., Petrella, C., Ferraguti, G., Minni, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315384 · Cited by 27
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., & Pan, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119571 · Cited by 29
Tian, T., Xie, X., Yi, W., Zhou, Y., Xu, Y., Wang, Z., Zhang, J., Lin, M., Zhang, R., Lv, Z., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113362 · Cited by 27
Self-citationExpression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 27
Li, L., Ye, Q., Ma, J., Wang, Z., Liu, T., Lei, Y., Lu, M., Kang, J., Xiang, H., Li, B., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.013 · Cited by 29
van Caloen, G., & Machiels, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000513 · Cited by 26
Solomon, B. M., Callejo, A., Bar, J., Berchem, G., Bazhenova, L. A., Saintigny, P., Wunder, F., Raynaud, J., Girard, N., Lee, J. J., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4635 · Cited by 24
O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma
Zhou, P., Chang, W.-Y., Gong, D.-A., Huang, L., Liu, R., Liu, Y., Xia, J. L., Wang, K., Tang, N., & Huang, A. (2023) · Oncogene · doi:10.1038/s41388-022-02589-z · Cited by 26
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 24
Zhang, Z., Shi, X., Ji, J., Guo, Y., Peng, Q., Hao, L., Xue, Y., Liu, Y.-W., Li, C., Lu, J., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0978-2 · Cited by 28
Nayyar, N., de Sauvage, M. A., Chuprin, J., Sullivan, E. M., Singh, M., Torrini, C., Zhang, B. S., Bandyopadhyay, S., Daniels, K. A., Alvarez-Breckenridge, C. A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0433 · Cited by 26
CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes
Михайловна, Д. А., Bilyalov, A. I., Nikolaev, S., Khalikov, N., Isaeva, D., Levina, Y. G., Makarova, M. V., Nemtsova, M. V., Chernevskiy, D. K., Sagaydak, O. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123343 · Cited by 28
Recent advances in developing targeted protein degraders
Cheng, B., Li, H., Peng, X., Chen, J., Shao, C., & Kong, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117212 · Cited by 28
Luo, H., Hu, B., Gu, X.-R., Chen, J., Fan, X., Zhang, W., Wang, R., He, X.-D., Guo, W., Dai, N., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02201-w · Cited by 25
Yang, Y., Cao, L., Xu, X., Li, D., Deng, Y., Li, L., Zeng, B., Jiang, H., Shan, L., Huang, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03986-5 · Cited by 25
Self-citationXiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 28
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory
West, J., Robertson‐Tessi, M., Luddy, K. A., Park, D. S., Williamson, D. F. K., Harmon, C., Khong, H. T., Brown, J. S., & Anderson, A. R. A. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00078 · Cited by 25
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity
Xiong, W., Deng, H., Huang, C., Zen, C., Jian, C., Ye, K., Zhong, Z., Zhao, X., & Zhu, L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.027 · Cited by 25
Karami, S., Sattarifard, H., Kiumarsi, M., Sarabandi, S., Taheri, M., Hashemi, M. M., Bahari, G., & Ghavami, S. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.10.3115 · Cited by 24
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 26
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
Tang, T., Huang, X., Zhang, G., Lu, M., Hong, Z., Wang, M., Huang, J., Zhi, X., & Liang, T. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004129 · Cited by 25
Wang, Y., Fan, J., Chen, T., Xu, L., Liu, P., Xiao, L., Wu, T., Zhou, Q., Zheng, Q., Liu, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.975623 · Cited by 25
Exosomes; multifaceted nanoplatform for targeting brain cancers
Mardi, N., Salahpour‐Anarjan, F., Nemati, M., Baher, N. S., Rahbarghazi, R., & Zarebkohan, A. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216077 · Cited by 25
Wekking, D., Leoni, V. P., Lambertini, M., Dessì, M., Pretta, A., Cadoni, A., Atzori, L., Scartozzi, M., & Solinas, C. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.10.001 · Cited by 26
Cheng, Y., Song, Z., Chen, J., Tang, Z., & Wang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25895 · Cited by 26
Activation of phagocytosis by immune checkpoint blockade
Li, C., Lai, Y., Hsu, J. L., & Hung, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0657-5 · Cited by 27
The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway
Tang, H., Pang, X., Li, S., & Tang, L. (2024) · Biomolecules · doi:10.3390/biom14070738 · Cited by 25
Hong, Y., Chen, Q., Wang, Z., Zhang, Y., Li, B., Guo, H., Huang, C., Kong, X., Mo, P., Xiao, N., et al. (2024) · Advanced Science · doi:10.1002/advs.202310037 · Cited by 24
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 27
Hu, Q., Shi, Y., Wang, H., Li, B., & Xu, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00627-6 · Cited by 27
Self-citationGiugliano, F., Angelis, C. D., Pistilli, B., Viale, G., Bianchini, G., Giuliano, M., Malorni, L., Salimbeni, B. T., Espósito, A., Giordano, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102980 · Cited by 26
SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle
Gautam, D., Johnson, B. A., Mac, M., & Moody, C. A. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007367 · Cited by 25
Tundo, G. R., Sbardella, D., Oddone, F., Kudriaeva, A. A., Lacal, P. M., Belogurov, A. A., Graziani, G., & Marini, S. (2021) · Cancers · doi:10.3390/cancers13194852 · Cited by 25
Palicelli, A., Bonacini, M., Croci, S., Magi‐Galluzzi, C., Cañete‐Portillo, S., Chaux, A., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., et al. (2021) · Cells · doi:10.3390/cells10113165 · Cited by 24
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
Shrestha, M., Wang, D., Ben‐David, Y., & Zacksenhaus, E. (2023) · Oncogenesis · doi:10.1038/s41389-023-00475-1 · Cited by 25
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Hamid, R., Alaziz, M., Mahal, A. S., Ashton, A. W., Halama, N., Jaeger, D., Jiao, X., & Pestell, R. G. (2023) · Cells · doi:10.3390/cells12182237 · Cited by 28
Gao, Y., Feng, C., Ma, J., & Yan, Q. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116048 · Cited by 26
Senescence and senolysis in cancer: The latest findings
Imawari, Y., & Nakanishi, M. (2024) · Cancer Science · doi:10.1111/cas.16184 · Cited by 25
Prognostic biomarkers for immunotherapy in esophageal cancer
Xu, T., Jin, M., Wang, L., Zhang, D., Yin, Y., & Shen, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420399 · Cited by 24
Li, Y., Wang, Y., Jing, Y., Zhu, Y., Huang, X., Wang, J., Dilraba, E., & Guo, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02032-1 · Cited by 23
Self-citationASB7 is a negative regulator of H3K9me3 homeostasis
Zhou, L., Chen, Z., Zou, Y., Zhang, X., Wang, Z., Zhu, H., Lin, J., Huang, Z., Zheng, L., Chen, J., et al. (2025) · Science · doi:10.1126/science.adq7408 · Cited by 25
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Han, C., Zhang, A., Liu, Z., Moore, C., & Fu, Y. (2020) · Oncogene · doi:10.1038/s41388-020-01575-7 · Cited by 22
Regulation of Hedgehog Signal Transduction by Ubiquitination and Deubiquitination
Zhang, Q., & Jiang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413338 · Cited by 23
Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation
Wei, M., Mo, Y., Liu, J., Zhai, J., Li, H., Xu, Y., Peng, Y., Tang, Z., Wei, T., Yang, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835603 · Cited by 23
Self-citationCombination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 26
Krasniqi, E., Goeman, F., Pulito, C., Palcau, A. C., Ciuffreda, L., Lisa, F. S. D., Filomeno, L., Barba, M., Pizzuti, L., Cappuzzo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314534 · Cited by 23
Inhibition of CK2/ING4 Pathway Facilitates Non‐Small Cell Lung Cancer Immunotherapy
Gou, Q., Chen, H., Chen, M., Shi, J., Jin, J., Liu, Q., & Hou, Y. (2023) · Advanced Science · doi:10.1002/advs.202304068 · Cited by 22
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 24
Hong, Z., Liu, F., & Zhang, Z. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00552-0 · Cited by 25
Tian, S., Xu, M., Geng, X., Fang, J., Xu, H., Xue, X., Hu, H., Zhang, Q., Yu, D., Guo, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202410285 · Cited by 22
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., Ross, E. A., & El‐Deiry, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00150-8 · Cited by 22
SPOP-mutant prostate cancer: Translating fundamental biology into patient care
Bernasocchi, T., & Theurillat, J.-P. P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.024 · Cited by 22
CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
Cheung, A., Chenoweth, A. M., Quist, J., Sow, H. S., Malaktou, C., Ferro, R., Hoffmann, R. M., Osborn, G., Sachouli, E., French, E., et al. (2022) · Cancers · doi:10.3390/cancers14143361 · Cited by 22
Generation, secretion and degradation of cancer immunotherapy target PD-L1
Shen, D., Bi, Y., Pang, J., Zhao, L., Zhao, L., Gao, Y., Wang, B., Liu, H., Liu, Y., Wang, N., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04431-x · Cited by 24
Pandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 24
Kumar, A., Ramani, V., Bharti, V., Bellan, D. D. L., Saleh, N., Uzhachenko, R. V., Shen, C., Arteaga, C. L., Richmond, A. J., Reddy, S. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006019 · Cited by 23
Targeting VCP potentiates immune checkpoint therapy for colorectal cancer
Wang, F., Qi, Q., Qin, B., Wang, Y., Huang, Y., Li, Q., Shen, X. H., Wang, X., Yang, S., Pan, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113318 · Cited by 23
Self-citationTRIM28 in cancer and cancer therapy
Li, K., Wang, H., Jiang, B., & Jin, X. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1431564 · Cited by 23
Self-citationBlocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget
Huang, X., Zhang, X., Bai, X., & Liang, T. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0348-4 · Cited by 22
Recent Findings in the Posttranslational Modifications of PD-L1
Li, S., Zhou, J., Wang, Y., Nie, R., Chen, J., & Xie, D. (2020) · Journal of Oncology · doi:10.1155/2020/5497015 · Cited by 22
Development of a prognostic model of glioma based on immune‑related genes
Wang, J., Wang, H., Zhu, B.-L., Wang, X., Qian, Y., Xie, L., Wang, W., Zhu, J., Chen, X., Wang, J., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12377 · Cited by 22
Self-citationCMTM6 as a master regulator of PD-L1
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03171-y · Cited by 25
Teh, J. L. F., Erkes, D. A., Cheng, P. F., Tiago, M., Wilski, N. A., Field, C. O., Chervoneva, I., Levesque, M. P., Xu, X., Dummer, R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0743 · Cited by 22
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Ren, X., Wang, L., Liu, L., & Liu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392546 · Cited by 23
Synergistic targeting strategies for prostate cancer
Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 22
Fan, Y., Hou, T., Dan, W., Zhu, Y., Liu, B., Wei, Y., Wang, Z., Gao, Y., Zeng, J., & Li, L. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00951-y · Cited by 21
Self-citationEffects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle
Chai, I., Kornyeyev, D., Hsieh, E. J., Magombedze, G., Stapleton, L., Hung, M., Kwon, H. J., Stefanutti, E., Belzile, J.-P., Czerwieniec, G. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25417-6 · Cited by 21
Han, Y., Fan, X., Fan, L., Wu, Y., Zhou, Z., Wang, G., Guo, L., Gao, W., Chen, Y., & Gao, Q. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154672 · Cited by 23
Ye, G., Sun, X., Li, J., Mai, Y., Gao, R., & Zhang, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.12.016 · Cited by 21
Self-citationLi, Z., Xue, H., Li, J., Zheng, Z., Liu, Z., Dong, X., Wang, H., Chen, J., & Xu, S. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03007-w · Cited by 23
Self-citationMiR‐520b promotes the progression of non‐small cell lung cancer through activating Hedgehog pathway
Liu, X., Liu, J., Zhang, X., Tong, Y., & Gan, X. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13909 · Cited by 21
Zeng, X., Zhong, M., Yang, Y., Wang, Z., & Zhu, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16383 · Cited by 21
Self-citationDeubiquitination and Stabilization of PD-L1 by USP21Preprint
Yang, S., Wu, Y., Yan, H., Shan, B., Zhou, D., Liu, X., Mao, X., Zhou, S., Zhao, Q., & Xia, H. (2021) · doi:10.21203/rs.3.rs-137970/v1 · Cited by 21
Garrido-Castro, A. C., Graham, N., Ali, L. R., Herold, C. I., Desrosiers, J., Do, K., Parsons, H. A., Li, T., Goel, S., DiLullo, M. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010430 · Cited by 20
Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549520 · Cited by 22
Self-citationBreaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 21
Padhye, A., Konen, J. M., Rodriguez, B. L., Fradette, J. J., Ochieng, J. K., Diao, L., Wang, J., Lü, W., Solis, L. S., Batra, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148392 · Cited by 22
Hypophosphorylated pRb knock‐in mice exhibit hallmarks of aging and vitamin C‐preventable diabetes
Jiang, Z., Li, H., Schroer, S. A., Voisin, V., Ju, Y., Pacal, M., Erdmann, N., Shi, W., Chung, P. E. D., Deng, T., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2020106825 · Cited by 18
Tumor immune checkpoints and their associated inhibitors
Gao, Z., Ling, X., Shi, C., Wang, Y., & Lin, A. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200195 · Cited by 21
Zhang, Z., Wang, G., Zhong, K., Chen, Y., Yang, N., Lu, Q., Yuan, B., Wang, Z., Li, H., Guo, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03875-4 · Cited by 20
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Mounika, P., Gurupadayya, B., Kumar, H. Y., & Bannimath, N. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230320144713 · Cited by 23
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 22
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21
Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment
Liu, J., Cheng, M., Xu, J., Liang, Y., Yin, B., & Liang, J. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2304565 · Cited by 20
Wu, J., Wang, W., Gao, L., Shao, X., & Wang, X. (2024) · Cancer · doi:10.1002/cncr.35270 · Cited by 22
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
